Health & Fitness
Mon, November 25, 2024Thu, November 14, 2024Tue, November 12, 2024Sat, June 10, 2017Sat, June 3, 2017Wed, May 31, 2017Wed, May 17, 2017Fri, May 12, 2017Thu, May 11, 2017Tue, May 9, 2017Thu, May 4, 2017Thu, April 20, 2017Fri, April 14, 2017Thu, March 23, 2017Fri, March 17, 2017Thu, March 9, 2017Sat, March 4, 2017Fri, March 3, 2017Thu, March 2, 2017Wed, February 15, 2017Mon, February 13, 2017Wed, February 8, 2017Thu, February 2, 2017Fri, January 13, 2017Wed, January 11, 2017Wed, January 4, 2017Fri, December 16, 2016Thu, December 15, 2016Mon, December 12, 2016Thu, December 8, 2016Wed, November 23, 2016Mon, November 14, 2016Sun, November 13, 2016Wed, November 9, 2016Thu, November 3, 2016Wed, November 2, 2016Mon, October 17, 2016Sat, October 8, 2016Thu, October 6, 2016Wed, October 5, 2016Mon, October 3, 2016Fri, September 30, 2016Thu, September 29, 2016Tue, September 27, 2016Mon, September 26, 2016Fri, September 23, 2016Thu, September 22, 2016Wed, September 21, 2016Tue, September 20, 2016Mon, September 19, 2016Sun, September 18, 2016Fri, September 16, 2016Thu, September 15, 2016Wed, September 14, 2016Mon, September 12, 2016Fri, September 9, 2016Thu, May 9, 2013Wed, May 8, 2013Tue, May 7, 2013Mon, May 6, 2013Sun, May 5, 2013Fri, May 3, 2013Thu, May 2, 2013Wed, May 1, 2013Tue, April 30, 2013Mon, April 29, 2013Sun, April 28, 2013Fri, April 26, 2013Thu, April 25, 2013Wed, April 24, 2013Tue, April 23, 2013BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
Published in Health and Fitness on Friday, May 3rd 2013 at 5:30 GMT by Market Wire
BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013... -- LYNBROOK, N.Y., May 3, 2013 /PRNewswire/ --
LYNBROOK, N.Y., May 3, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: [ BSTC ]), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S., announced today that it will host a conference call and live audio webcast at 8:30 a.m. EDT on Friday, May 10, 2013 to report its first quarter 2013 financial results and provide a corporate update.
In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at [ www.biospecifics.com ] or you may use the link: [ http://www.videonewswire.com/event.asp?id=93618 ].
A replay of the call will be available one hour after the end of the conference on May 10, 2013 until 9:00 a.m. EDT on May 27, 2013. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10028021. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics' website at [ www.biospecifics.com ].
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc., and is approved for Dupuytren's contracture in the EU and Canada. XIAFLEX is also in clinical development for the treatment of several additional promising indications. The U.S. Food & Drug Administration (FDA) has accepted Auxilium's supplemental Biologics License Application (sBLA) for filing for XIAFLEX for the potential treatment of Peyronie's disease. The FDA is expected to take action on the application by September 6, 2013, and, if approved, XIAFLEX will be the first and only biologic treatment indicated for Peyronie's disease. Auxilium is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite. Auxilium has reported positive top-line data from a Phase IIa frozen shoulder study and expects to initiate the next phase trial in the second half of 2013. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human and canine lipomas, which are both in Phase II clinical trials, with top-line data from both trials expected in the second half of 2013. Auxilium is currently partnered with Asahi Kasei Pharma Corporation for the development and commercialization of XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan and with Actelion Pharmaceuticals Ltd. for these same indications in Canada, Australia, Brazil and Mexico. For more information, please visit [ www.biospecifics.com ].
SOURCE BioSpecifics Technologies Corp.
RELATED LINKS
[ http://www.biospecifics.com ]
